ArticleFrontiers in cellular and infection microbiology2026
Evaluation of neurotoxicity of drugs from morphological and electrophysiological endpoints using human iPSC-derived neural cell models.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Genome-edited human induced pluripotent stem cells (iPSCs) were first generated in 2007, and have been applied in pharmaceutical research, development, and clinical therapy as an Methods: In this study, we developed a hiPSC-derived neural model that is suitable for testing neurospecific morphology and electrophysiology endpoints. Results: The research results showed that oxaliplatin and emodin at concentrations higher than 10 μg/mL, phenytoin sodium at concentrations exceeding 50 μg/mL, acrylamide and amantadine at concentrations exceeding 100 μg/mL, as well as aconitine and isoniazid (100 μg/mL) have a toxic effect on neurite outgrowth (p<0.05, p<0.01). No significant neurite outgrowth toxicity was observed in any of the dose groups of ethambutol. In MEA detection, phenytoin sodium and amantadine reduced the Number of Spikes, Mean Firing Rates, Number of Bursts, and Synchrony Index in a concentration-dependent manner. Phenytoin sodium, amantadine, and nano-Iron oxide all exhibited potent inhibitory effects on neuronal firing. Ethambutol exhibited a time-dependent and dose-dependent excitatory/inhibitory effect. The effect of isoniazid on neural electrical activity shifted from inhibition to excitation with the increase of administration dose and the extension of exposure time. This model enables a more comprehensive evaluation of neurotoxicity in neurotherapeutic drugs, nano-pharmaceuticals, and environmental organic compounds from the perspective of changes in neurite outgrowth and neural network functionality. Discussion: The method has specific test endpoints and high sensitivity, and can achieve high-throughput drug screening, which is expected to be applied to the safety risk assessment and scientific supervision of drugs with potential neurotoxicity, especially various types of neurotherapeutic drugs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.